Improve Human Health to Preserve Patients’ Dignity

Leading new drug development for genitourinary tumors & other related diseases

Highlights

Asieris’ progress in MIBC receives renewed attention with its inclusion in ASCO 2023

Products

Vesique^®(APL-1202) | Cevira^® (APL-1702)

Treatment Areas

Bladder Cancer

Lack of oral therapy for non-muscle invasive bladder cancer (NMIBC) patients with improved patient compliance and less adverse effects from intravesical administration.

Precancerous Cervical Dysplasia

In urgent need of safe and effective options for patients with cervical precancerous lesions, currently treated by traditional surgical methods.

Global Partnership

News & Updates

Asieris’ progress in MIBC receives renewed attention with its inclusion in ASCO 2023

Asieris Deepens Strategic Partnership with UroViu to Further Develop Integrated Diagnosis and Treatment Platform for Bladder Cancer

Asieris Releases 2022 Annual Report: Make Steady Progress in its Clinical Development, Global Expansion to Treat Genitourinary Tumors, and Implementing its Commercialization Strategy to Provide Integrated Diagnosis-to-Treatment Solutions

Highlights of Asieris Pharmaceuticals 2022 Annual Report

Asieris’ subsidiary makes significant progress in its commercialization strategy by obtaining the “Drug Distribution License”

February 20, 2023

NMPA accepted the registration applications for Uro-G and Uro-3500

Technology Platform